Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135594 | 0.85 | KMT2A (0.47) | KMT2AMEN1POLBPLA2G1BATG4B | |
| SCHEMBL20134746 | 0.75 | KMT2A (0.48) | KMT2AMEN1POLBPLA2G1BATG4B | |
| SCHEMBL20134899 | 0.73 | KMT2A (0.46) | KMT2AMEN1POLBPLA2G1BATG4B | |
| SCHEMBL20135176 | 0.73 | ADAM17 (0.40) | KMT2AMEN1POLB | |
| SCHEMBL20134863 | 0.73 | ADAM17 (0.40) | KMT2AMEN1POLB | |
| SCHEMBL29688786 | 0.73 | ADAM17 (0.40) | KMT2AMEN1POLB | |
| SCHEMBL29688931 | 0.73 | ADAM17 (0.40) | KMT2AMEN1POLB | |
| SCHEMBL20134861 | 0.73 | ADAM17 (0.40) | KMT2AMEN1POLB | |
| SCHEMBL24529787 | 0.72 | KMT2A (0.51) | KMT2AMEN1POLBPLA2G1BATG4B | |
| SCHEMBL1808218 | 0.72 | MGLL (0.66) | KMT2AMEN1POLBADRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | KMT2A 2568/4885MEN1 3735/4885POLB 1991/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | KMT2A 2539/4885MEN1 2913/4885POLB 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.